StreetInsider.com News Articles

Minerva Neurosciences to Participate in Two Upcoming Investor Conferences

Fri, 28 Aug 2026 08:00:00 -0400

BURLINGTON, Mass., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that management will participate in two upcoming investor conferences.

Wells Fargo Healthcare Conference
Date: Tuesday, September 8
Format: 1x1 meetings
Location: New York, NY

2026 Cantor Global Healthcare Conference
Date: Wednesday, September 9
Format: Fireside chat and 1x1 meetings
Time: 2:45 – 3:15 PM EDT
Location: New York, NY

Minerva Neurosciences to Participate in Two Upcoming Investor Conferences

Fri, 28 Aug 2026 08:00:00 -0400

Wells Fargo Healthcare Conference
Date: Tuesday, September 8
Format: 1x1 meetings
Location: New York, NY

2026 Cantor Global Healthcare Conference
Date: Wednesday, September 9
Format: Fireside chat and 1x1 meetings
Time: 2:45 – 3:15 PM EDT
Location: New York, NY

Form 3 Minerva Neurosciences, For: Aug 10 Filed by: Reilly Joseph H.

Thu, 20 Aug 2026 16:40:00 -0400

si-local-file:///var/storage/secattach/20260820/26956731.html

Form 3 Minerva Neurosciences, For: Aug 10 Filed by: Reilly Joseph H.

Thu, 20 Aug 2026 16:40:00 -0400

si-local-file:///var/storage/secattach/20260820/26956731.html

Form 3 Minerva Neurosciences, For: Aug 10 Filed by: Aliquo Anthony

Thu, 20 Aug 2026 16:38:00 -0400

si-local-file:///var/storage/secattach/20260820/26956706.html

Form 3 Minerva Neurosciences, For: Aug 10 Filed by: Aliquo Anthony

Thu, 20 Aug 2026 16:38:00 -0400

si-local-file:///var/storage/secattach/20260820/26956706.html

Form SCHEDULE 13G/A Minerva Neurosciences, Filed by: BALYASNY ASSET MANAGEMENT L.P.

Fri, 14 Aug 2026 06:09:00 -0400

si-local-file:///var/storage/secattach/20260814/26924120.html

Form SCHEDULE 13G/A Minerva Neurosciences, Filed by: BALYASNY ASSET MANAGEMENT L.P.

Fri, 14 Aug 2026 06:09:00 -0400

si-local-file:///var/storage/secattach/20260814/26924120.html

Jefferies Upgrades Minerva Neurosciences (NERV) to Buy

Fri, 14 Aug 2026 04:04:19 -0400

Jefferies analyst Andrew Tsai upgraded Minerva Neurosciences (NASDAQ: NERV) from Hold to Buy with a price target of $10.00 (from $7.50).

The analyst comments: “For NSS, oral roluperidone produced (+) Phase IIb data (C03 study) in 2016 (stat-sig) but mixed Phase III results in 2020 (C07 study) - arguably due to a high placebo effect (vs a lack of drug activity). After receiving an RTF in Oct# 2022 and a CRL in Feb 2024, NERV gained FDA alignment (Aug 2025) to run another Phase III NSS study. We think the regulatory pathway has become more favorable, with the agency formally recognizing

Jefferies Upgrades Minerva Neurosciences (NERV) to Buy

Fri, 14 Aug 2026 04:04:19 -0400

Jefferies analyst Andrew Tsai upgraded Minerva Neurosciences (NASDAQ: NERV) from Hold to Buy with a price target of $10.00 (from $7.50).

Form SCHEDULE 13G/A Minerva Neurosciences, Filed by: FARALLON CAPITAL MANAGEMENT, L.L.C.

Thu, 13 Aug 2026 17:18:00 -0400

si-local-file:///var/storage/secattach/20260813/26922765.html

Form SCHEDULE 13G/A Minerva Neurosciences, Filed by: FARALLON CAPITAL MANAGEMENT, L.L.C.

Thu, 13 Aug 2026 17:18:00 -0400

si-local-file:///var/storage/secattach/20260813/26922765.html

Form 8-K Minerva Neurosciences, For: Aug 10

Wed, 12 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260812/26912762.html

Form 8-K Minerva Neurosciences, For: Aug 10

Wed, 12 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260812/26912762.html

Minerva Neurosciences (NERV) Tops Q2 EPS by 5c

Fri, 07 Aug 2026 08:03:05 -0400

Minerva Neurosciences (NASDAQ: NERV) reported Q2 EPS of ($0.14), $0.05 better than the analyst estimate of ($0.19).

For earnings history and earnings-related data on Minerva Neurosciences (NERV) click here.

Form 10-Q Minerva Neurosciences, For: Jun 30

Fri, 07 Aug 2026 07:31:00 -0400

si-local-file:///var/storage/secattach/20260807/26887540.html

Form 10-Q Minerva Neurosciences, For: Jun 30

Fri, 07 Aug 2026 07:31:00 -0400

si-local-file:///var/storage/secattach/20260807/26887540.html

Form 8-K Minerva Neurosciences, For: Aug 07

Fri, 07 Aug 2026 07:14:00 -0400

si-local-file:///var/storage/secattach/20260807/26887439.html

Form 8-K Minerva Neurosciences, For: Aug 07

Fri, 07 Aug 2026 07:14:00 -0400

si-local-file:///var/storage/secattach/20260807/26887439.html

Minerva Neurosciences Provides Second Quarter 2026 Financial Results and Business Updates

Fri, 07 Aug 2026 07:00:00 -0400

Confirmatory Phase 3 trial of roluperidone (MIN-101C19) ongoing with topline efficacy data expected 2H 2027

Scientific Advisory Board of leading experts in psychiatry and neuroscience established to guide the confirmatory Phase 3 trial of roluperidone

Roluperidone remains the only late-stage drug candidate for this high-need population

BURLINGTON, Mass., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported financial and business updates for the second quarter ended

Minerva Neurosciences Provides Second Quarter 2026 Financial Results and Business Updates

Fri, 07 Aug 2026 07:00:00 -0400

Confirmatory Phase 3 trial of roluperidone (MIN-101C19) ongoing with topline efficacy data expected 2H 2027

Scientific Advisory Board of leading experts in psychiatry and neuroscience established to guide the confirmatory Phase 3 trial of roluperidone

Roluperidone remains the only late-stage drug candidate for this high-need population

Form 4 Minerva Neurosciences, For: Aug 03 Filed by: Kaul Inderjit

Mon, 03 Aug 2026 18:05:00 -0400

si-local-file:///var/storage/secattach/20260803/26859589.html

Form 4 Minerva Neurosciences, For: Aug 03 Filed by: Kaul Inderjit

Mon, 03 Aug 2026 18:05:00 -0400

si-local-file:///var/storage/secattach/20260803/26859589.html

Form SCHEDULE 13G/A Minerva Neurosciences, Filed by: FEDERATED HERMES, INC.

Wed, 08 Jul 2026 07:52:00 -0400

si-local-file:///var/storage/secattach/20260708/26744368.html

Form SCHEDULE 13G/A Minerva Neurosciences, Filed by: FEDERATED HERMES, INC.

Wed, 08 Jul 2026 07:52:00 -0400

si-local-file:///var/storage/secattach/20260708/26744368.html